Bruker (NASDAQ:BRKR) Price Target Raised to $60.00

Bruker (NASDAQ:BRKR) had its target price increased by stock analysts at Bank of America from $43.00 to $60.00 in a report released on Monday,Benzinga reports. The firm presently has a “buy” rating on the medical research company’s stock. Bank of America‘s price target would indicate a potential upside of 32.95% from the stock’s current price.

Several other research analysts also recently issued reports on BRKR. Wells Fargo & Company reissued an “overweight” rating on shares of Bruker in a research report on Monday. Rothschild Redb upgraded shares of Bruker to a “strong-buy” rating in a research note on Thursday, November 20th. Zacks Research upgraded Bruker from a “strong sell” rating to a “hold” rating in a research report on Monday, December 8th. Wolfe Research raised Bruker from a “peer perform” rating to an “outperform” rating and set a $60.00 price objective for the company in a research note on Wednesday. Finally, UBS Group lifted their target price on Bruker from $40.00 to $43.00 and gave the company a “neutral” rating in a research note on Tuesday, November 4th. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, six have assigned a Hold rating and two have given a Sell rating to the company. According to MarketBeat, Bruker has an average rating of “Hold” and a consensus target price of $52.15.

Bruker Stock Performance

Shares of Bruker stock opened at $45.13 on Monday. The company has a market cap of $6.86 billion, a PE ratio of -282.06, a P/E/G ratio of 6.64 and a beta of 1.17. The business has a 50-day simple moving average of $41.68 and a 200-day simple moving average of $38.33. Bruker has a one year low of $28.53 and a one year high of $64.64. The company has a debt-to-equity ratio of 0.81, a quick ratio of 0.91 and a current ratio of 1.85.

Bruker (NASDAQ:BRKR) last posted its earnings results on Monday, November 3rd. The medical research company reported $0.45 earnings per share for the quarter, topping the consensus estimate of $0.33 by $0.12. The firm had revenue of $860.50 million during the quarter, compared to analysts’ expectations of $847.40 million. Bruker had a positive return on equity of 15.45% and a negative net margin of 0.61%.The firm’s revenue was down .5% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.60 earnings per share. Bruker has set its FY 2025 guidance at 1.850-1.90 EPS. On average, equities research analysts forecast that Bruker will post 2.69 EPS for the current fiscal year.

Insider Activity

In other Bruker news, Director John A. Ornell sold 6,233 shares of the firm’s stock in a transaction dated Thursday, November 6th. The shares were sold at an average price of $39.00, for a total transaction of $243,087.00. Following the sale, the director directly owned 35,212 shares of the company’s stock, valued at $1,373,268. This trade represents a 15.04% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 27.30% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Bruker

Hedge funds have recently modified their holdings of the stock. Orbis Allan Gray Ltd purchased a new position in shares of Bruker in the 2nd quarter worth about $192,735,000. AQR Capital Management LLC increased its position in Bruker by 125.3% during the 2nd quarter. AQR Capital Management LLC now owns 3,326,820 shares of the medical research company’s stock worth $137,065,000 after purchasing an additional 1,850,215 shares in the last quarter. Sculptor Capital LP increased its position in Bruker by 18.3% during the 2nd quarter. Sculptor Capital LP now owns 3,074,801 shares of the medical research company’s stock worth $126,682,000 after purchasing an additional 476,363 shares in the last quarter. Brown Advisory Inc. raised its holdings in Bruker by 13.9% in the second quarter. Brown Advisory Inc. now owns 2,746,163 shares of the medical research company’s stock valued at $113,142,000 after buying an additional 336,026 shares during the period. Finally, Vaughan Nelson Investment Management L.P. lifted its position in Bruker by 61.6% during the third quarter. Vaughan Nelson Investment Management L.P. now owns 2,090,155 shares of the medical research company’s stock valued at $67,909,000 after buying an additional 796,510 shares in the last quarter. 79.52% of the stock is owned by institutional investors and hedge funds.

Bruker Company Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.